As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter.